Leerink Partnrs Upgrades Shattuck Labs (NASDAQ:STTK) to “Strong-Buy”

Shattuck Labs (NASDAQ:STTK) was upgraded by investment analysts at Leerink Partnrs to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

Separately, Leerink Partners started coverage on Shattuck Labs in a report on Monday. They issued an “outperform” rating and a $4.00 target price for the company. Four investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

Shattuck Labs Trading Down 0.9 %

NASDAQ:STTK opened at $1.16 on Monday. The firm has a market cap of $55.38 million, a PE ratio of -0.76 and a beta of 1.66. The stock has a fifty day moving average price of $1.24 and a 200 day moving average price of $1.60. Shattuck Labs has a 12-month low of $0.94 and a 12-month high of $11.76.

Institutional Trading of Shattuck Labs

A number of hedge funds and other institutional investors have recently made changes to their positions in STTK. Zacks Investment Management acquired a new stake in shares of Shattuck Labs during the fourth quarter worth about $25,000. Virtu Financial LLC acquired a new stake in shares of Shattuck Labs during the fourth quarter worth about $30,000. Atom Investors LP acquired a new position in Shattuck Labs in the 3rd quarter valued at about $35,000. Readystate Asset Management LP acquired a new position in Shattuck Labs in the 3rd quarter valued at about $39,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in Shattuck Labs in the 4th quarter valued at about $45,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.